from NORML/January 7, 2022
Numerous minor cannabinoids found in the cannabis plant possess therapeutic properties that may hold clinical significance, according to a review paper published in the journal Frontiers of Pharmacology.
A team of US investigators affiliated with the University of South Carolina and Doane University in Nebraska summarized data on the potential therapeutic applications of a number of secondary cannabinoids, including CBN (cannabinol), CBC (cannabichromine), cannabigerol (CBG), and tetrahydrocannabivarin (THCV).
Specifically, authors highlighted the analgesic and anti-inflammatory properties of various ancillary cannabinoids, including CBG, CBC, THCV, and CBN.
They acknowledged that CBN also “shows promise as an antibacterial agent and [as] an appetite stimulant,” but cautioned that it has shown inconsistent results as a sleep aid.
Several of these minor cannabinoids, such as CBG and CBC, also possess anti-cancer properties, while THCV “regulates blood glucose levels, suggesting it might be useful in weight reduction and treating diabetes.” THCV has also demonstrated anti-epileptic and neuroprotective properties.
Another cannabinoid highlighted by the authors, cannabidivarin (CBDV) possesses anti-seizure activity and may possess therapeutic utility in the treatment of autism, muscular dystrophy, and as an anti-emetic agent.
A number of these minor cannabinoids have “also shown promise in the treatment of skin disorders,” investigators reported.
from:
